Enveric BiosciencesENVB
ENVB
About: Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.
Employees: 26
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
18% more funds holding
Funds holding: 17 [Q3] → 20 (+3) [Q4]
15% more capital invested
Capital invested by funds: $337K [Q3] → $387K (+$49.6K) [Q4]
2.64% more ownership
Funds ownership: 7.97% [Q3] → 10.61% (+2.64%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$10
510%
upside
Avg. target
$10
510%
upside
High target
$10
510%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Vernon Bernardino 21% 1-year accuracy 13 / 63 met price target | 510%upside $10 | Buy Reiterated | 6 Mar 2025 |
Financial journalist opinion
Based on 3 articles about ENVB published over the past 30 days
Neutral
Business Wire
1 week ago
Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the company will build on its recent business development momentum by soliciting Requests-For-Proposal (“RFPs”) for license or sale of its PsyAI™ trademark portfolio as a means of maximizing value for an asset.
Neutral
Business Wire
2 weeks ago
Enveric Biosciences CEO Issues Letter to Shareholders
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that Joseph Tucker, Ph.D., CEO and Director, has issued a Letter to Shareholders to provide an update on the Company's development program and recent events. The full text of the letter follows. A MESSAGE FROM.
Neutral
Business Wire
2 weeks ago
Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,195,439 (the ‘439 patent) on January 14, 2025. Entitled “Cl-Substituted Isopropylamine Fused Heterocyclic Mescaline Derivatives,” th.
Neutral
Business Wire
1 month ago
Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, is pleased to announce that its wholly-owned subsidiary, Akos Biosciences, Inc. (“Akos”), has entered into two licensing agreements with Restoration Biologics LLC (“Restoration Biologics”), a biotechnology company focused on.
Neutral
Business Wire
1 month ago
Enveric Biosciences Announces Closing of $5 Million Public Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced the closing of its previously announced public offering of an aggregate of 1,666,666 shares of its common stock (or common stock equivalents in lieu thereof), Series A warrants to purchase up to 1,666,66.
Neutral
Business Wire
1 month ago
Enveric Biosciences Announces Pricing of $5 Million Public Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced the pricing of a public offering of an aggregate of 1,666,666 shares of its common stock (or common stock equivalents in lieu thereof), Series A warrants to purchase up to 1,666,666 shares of common stoc.
Neutral
Business Wire
1 month ago
Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has received a Notice of Allowance (NOA) from the United States Patent and Trademark Office (USPTO) for a patent application pertaining to its EVM301 Series of molecules being developed as potential tr.
Neutral
Business Wire
2 months ago
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced Joseph Tucker, Ph.D., CEO, will participate in a panel discussion and present at the Sachs Associates 8th Annual Neuroscience Innovation Forum on January 12, 2025. Additionally, Enveric will attend Biotech Sho.
Neutral
Business Wire
3 months ago
Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued two U.S. Patents, Nos. 12,133,856 (the ‘856 patent) and 12,138,276,(the ‘276 patent) bringing the total number of issued patents supporting.
Neutral
Business Wire
3 months ago
Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogen small molecule therapeutics for the treatment of depression, anxiety, and other psychiatric disorders, today announced the completion of preclinical pharmacokinetic (“PK”) studies in rat and dog further supporting the oral bioavailability and targeted non-hallucinogenic profile of EB-003. The PK studies demonstrate.
Charts implemented using Lightweight Charts™